Cancer Clinical Trial
Official title:
Randomized Trial of Charity-based Incentives to Increase Physical Activity Among Cancer Survivors
Verified date | July 2019 |
Source | California Polytechnic State University-San Luis Obispo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators propose to examine whether linking daily activity with charity-based incentives motivates cancer survivors to initiate and maintain physical activity. Linking daily physical activity goals with a cancer specific charity incentive may provide a uniquely salient motivator that promotes increased physical activity among cancer survivors. The investigators will examine whether using activity monitors in combination with charitable incentives leads to greater increases in physical activity compared to activity monitors alone. Target participants includes cancer survivors who are not already active. Physical activity (e.g., steps per day, time in moderate-intensity activity) will be examined at baseline and following a 12-week intervention period using an activPAL accelerometer. After the baseline assessment, both groups will receive a fitbit monitor and informational material designed to increase physical activity. Participants in the fitbit+charity group will have donations made in their name to a cancer charity if they meet daily step goals. Physical activity levels will be monitored using the fitbit device for 6-weeks following the formal intervention period.
Status | Completed |
Enrollment | 51 |
Est. completion date | December 1, 2018 |
Est. primary completion date | December 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Adults = 18 years and <50 y, with diagnosed Adolescent or Young Adult cancer (diagnosed between 15-39y of age); 2. = 6 months post-cancer treatment 3. English speaking 4. Participate in <60 minutes of MVPA/week 5. Own a smartphone 6. Have access to computer 7. Participants must also pass a physical activity readiness questionnaire or receive medical clearance from their primary care physician or oncologist. Exclusion Criteria: 1. Joint, cardiovascular, or respiratory problem(s) precluding physical activity 2. Metastatic disease 3. Planned elective surgery or pregnancy during intervention/follow-up that would interfere with participation (e.g., breast reconstructive surgery). 4. Already using a wearable device >5 days per week |
Country | Name | City | State |
---|---|---|---|
United States | California Polytechnic State University | San Luis Obispo | California |
Lead Sponsor | Collaborator |
---|---|
California Polytechnic State University-San Luis Obispo |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Daily steps | Daily steps as measured by activPAL | 12 weeks - change from baseline to 12 weeks | |
Secondary | Participant retention | Proportion of participants retained of those randomized | 12 weeks | |
Secondary | Intervention Reach | Proportion of individuals who agree to participate of those who express an interest in participation | Baseline | |
Secondary | Step goal adherence | Proportion of weeks meeting physical activity goal as measured by fitbit | 1-12 weeks | |
Secondary | Daily Steps | Daily Steps as Measured by Fitbit | baseline to 12 weeks | |
Secondary | Sleep | Sleep as Measured by Fitbit | baseline to 12 weeks | |
Secondary | Sedentary time | Sedentary time as Measured by activPAL activity monitor | Change from baseline to 12 weeks | |
Secondary | Standing time | Standing time as Measured by activPAL | Change from baseline to 12 weeks | |
Secondary | Stepping time | Stepping time as Measured by activPAL | Change from baseline to 12 weeks | |
Secondary | Moderate-vigorous intensity physical activity (MVPA) time | MVPA time as Measured by activPAL | Change from baseline to 12 weeks | |
Secondary | Sedentary breaks/patterns | Sedentary breaks/patterns as Measured by activPAL | Change from baseline to 12 weeks | |
Secondary | Fatigue | Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a (Total Score range 8-40). higher score is more fatigue. | Change from baseline to 12 weeks | |
Secondary | Physical Function | Patient-Reported Outcomes Measurement Information System Physical Function Short Form 20a. Total score (range 20-100). Higher score is worse physical function | Change from baseline to 12 weeks | |
Secondary | Depression | Patient-Reported Outcomes Measurement Information System Depression Short Form 8a. Total score range 8-40. Higher score is more depressed. | Change from baseline to 12 weeks | |
Secondary | Attitudes Toward Charitable Giving | Attitudes Toward Charitable Giving Scale. Total of 20 questions with scores from 1-5, there are five domains higher score is more of a particular attitude. 1.) Inefficiency of Charitable Giving 2.) Efficiency of Charitable Giving 3.) Cynical Giving 4.) Altruistic Giving 5.) Purpose of Charity | Change from baseline to 12 weeks | |
Secondary | Behavioral Regulation in Exercise Questionnaire | Behavioral Regulation in Exercise Questionnaire -3. Contains 6 subscales Amotivation, external regulation, introjected regulation, identified regulation, integrated regulation, intrinsic regulation, each range from 0-16, higher values indicate more motivation in that domain. | Change from baseline to 12 weeks | |
Secondary | Barriers Self-efficacy Scale | Barriers Self-efficacy Scale. 15 items, total score range 0-1500. Higher indicated more self-efficacy | Change from baseline to 12 weeks | |
Secondary | Physical Activity Enjoyment | Physical Activity Enjoyment Scale. 18-item scale with 7-point bipolar rating. Total score range 18-126. Higher scores reflect greater levels of enjoyment. | Change from baseline to 12 weeks | |
Secondary | Pittsburg Sleep Quality Questionnaire | Pittsburg Sleep Quality Questionnaire. Total score. Greater than 5 indicated poor sleep quality. | Change from baseline to 12 weeks | |
Secondary | Exercise Self-efficacy Scale | Exercise Self-efficacy Scale. 6 items total score. Range 0-600, higher is more self-efficacy | Change from baseline to 12 weeks | |
Secondary | Intervention Maintenance | % of weeks adhered to step goal as measured by fitbit during 6-week follow-up period | 12-18 weeks | |
Secondary | Duration wore Fitbit | Duration wore Fitbit during during 6-week follow-up period | 12-18 weeks | |
Secondary | Exercise outcome expectations | Multidimensional Outcome Expectations for Exercise Scale. Total score (range 15-75), higher score means more multidimensional outcome expectations. | Change from baseline to 12 weeks | |
Secondary | Sleep disturbance | Patient-Reported Outcomes Measurement Information System Sleep Disturbance Form. Total score range 8-40. Higher score is more disturbance. | Change from baseline to 12 weeks | |
Secondary | Exercise Goal Setting | 10-item total score. Ranged from 10 to 50, higher score means more goal setting. Exercise Goal-Setting Scale. | Change from baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|